Join the Webcast: Novartis Dialogue to Explore Solutions to the Rise of Chronic Diseases in the Developing World
The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.
November 24, 2016 /3BL Media/ - The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.
Novartis Access and the Novartis Foundation will be discussing chronic diseases with experts from academia and non-profit organizations speaking and attending.
Speakers and panelists will include representatives from the World Health Organization, PATH, Pink Ribbon Red Ribbon, the London School of Hygiene & Tropical Medicine, Boston University and Emory University, as well as government delegates. Joerg Reinhardt, Novartis Chairman, will also deliver a keynote address.
In the morning, in collaboration with the Centre for Global Non-Communicable Diseases of the London School of Hygiene & Tropical Medicine, the Novartis Foundation will explore person-centered approaches to improving management and care for hypertension and its complications in lower-income areas.
In the afternoon, Novartis Access will present findings and learnings from the first year of implementation of an innovative social business approach to treat chronic diseases in lower-income countries. Speakers from both Novartis and its partners will present findings and discuss how they addressed challenges in the implementation, one year into the program.
We hope to have an engaging and interactive session. Join the conversation on Twitter: @Novartis @NovartisFDN #NovartisAccess #talkingNCDs. The webcast will be available to view on demand following the event on www.novartis.com and www.novartisfoundation.org.
Event details
|
Improving care for chronic patients in lower-income countries: the patient journey November 29, 2016 Join the conversation on Twitter: @Novartis @NovartisFDN #NovartisAccess #talkingNCDs Watch the webcast on demand following the event on www.novartis.com and www.novartisfoundation.org |
Agenda
|
09:30-09:40 |
Welcome |
|
09:40-09:50 |
Opening |
|
09:50-10:10 |
Integrated people-centered health services |
|
10:10-11:50 |
Case studies followed by facilitated group discussion
|
|
11:50-12:10 |
The Novartis commitment to expanding access to healthcare |
|
12:10-13:00 |
Break |
|
13:00-13:10 |
Welcome |
|
13:10-13:30 |
Key note speech (title TBC) |
|
13:30-14:45 |
Facilitated group discussion with moderator / panel Opening
|
|
14:45-15:00 |
Closing remarks |
About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative healthcare models that can have a transformational impact on the health of the poorest populations. We work hand-in-hand with our local and global partners to catalyze scalable and sustainable healthcare models to improve access and health outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing on interventions that aim to interrupt transmission. Everything we do is grounded in evidence and innovation, and our work is a continuous cycle of evaluation, adaptation and application. In 2015, the operational budget for the foundation was CHF 12 million and our programs reached 4.5 million people.
For more information, please visit:
www.youtube.com/novartisfoundation
Novartis Foundation is on Twitter. Sign up to follow @NovartisFDN at https://twitter.com/NovartisFDN
About Novartis Access
Novartis Access is a Group-wide program to help fight chronic diseases in lower-income countries. The Novartis Access portfolio focuses on affordability and availability of 15 on- and off-patent Novartis medicines addressing key diseases areas – cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The portfolio is offered as a basket to governments, non-governmental organizations (NGOs) and other public-sector customers at a price of USD 1 per treatment per month. Beyond the portfolio of medicines, Novartis Access offers capacity-building activities to support healthcare systems in preventing, diagnosing and treating NCDs. We are striving to roll out the program in 30 countries in the coming years – depending on governmental and stakeholder demand – aiming to reach 20 million patients per year by 2020.
Novartis Access is integrated in Novartis Social Business, a unit which includes the Novartis Malaria Initiative and the Novartis Healthy Family programs. This unit is operationally managed by Sandoz, the Novartis generics and biosimilars division.
www.novartisaccess.com
#NovartisAccess
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in approximately 180 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis (link is external)
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
|
Niamh Johnston |
Kiara Barnes |
